To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:7 Issue:10 Number:35 ISSN#:2564-2537
DOWNLOAD ESPAÑOL
Author Verified
Meta-Analysis
ACE Report #9456
Ace Report Cover Metabolic Disorders

Zoledronic Acid, alendronate, and risedronate reduce vertebral, nonvertebral, and hip fracture


How to Cite

OrthoEvidence. Zoledronic Acid, alendronate, and risedronate reduce vertebral, nonvertebral, and hip fracture. ACE Report. 2018;7(10):35. Available from: https://myorthoevidence.com/AceReport/Report/9456

Study Type:Meta analysis
OE Level Evidence:1
Journal Level of Evidence:N/A

Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses

Osteoporos Int. 2016 Nov;27(11):3289-3300

Contributing Authors:
X Ma J Zhou T Wang S Zhai

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

36 randomized controlled trials were included in this network meta-analysis to evaluate the comparative efficacy of different bisphosphonates in the management of osteoporosis. Nine different bisphosphonates were assessed in the included studies, with direct and indirect comparisons evaluated for vertebral fracture, nonvertebral fracture, hip fracture, wrist fracture, and any fracture. Zoledronic ...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.